Our preclinical studies showed that EGFRBi-armed T cells (EGFR BATs) lyse both established and patient-derived GBM cell lines, and induce multiple rounds of proliferation, endogenous tumor-specific cytotoxicity, and Th1 cytokine release without affecting T cell viability. The gene discussed is EGFR; the disease is neoplasm.